Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Human PEX produced in E. coli has a molecular mass of approximately 23 KDa.
Measured by its ability of suppressing angiogenesis in vitro.
>95% as determined by SDS-PAGE.
Lyophilized rHuPEX although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution rHuPEX should be stored at 4°C between 2-7 days and for future use below -18°C.For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.
PDB rendering based on 1ck7.Available structures: 1ck7,1cxw,1eak,1gen,1gxd,1j7m,1ks0,1rtg
PEX is the C-terminal hemopexin domain of Matrix Metalloproteinase-2. It has the activity of anti-angiogenesis, and a naturally occurring form of PEX can be detected in vivo. PEX can block angiogenesis and tumor growth in vivo, providing a potentially novel therapeutic approach for diseases associated with neovascularization. The appearance of PEX at sites of neovascularization may not only control normal angiogenesis, but when administered in sufficient quantities, may provide a naturally-occurring therapeutic inhibitor of diseases associated with angiogenesis.
calcium ion binding;catalytic activity;metal ion binding;metalloendopeptidase activity;protein binding;zinc ion binding.
CLG4; MONA; CLG4A; TBE-1; MMP-II; matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase); MMP2_HUMAN; 72 kDa type IV collagenase [Precursor]; EC188.8.131.52.; 72 kDa gelatinase; 72kD type IV collagenase; Gelatinase A; Matrix metalloproteinase-2; collagenase type IV-A; matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 72kD typeIV collagenase); matrix metalloproteinase-II; neutrophil gelatinase.